Business
NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle Technology
Toronto, Ontario--(Newsfile Corp. - March 25, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) (" ...
About this update from Nugen Medical Devices Inc
[{"type":"text","content":"NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle TechnologyToronto, Ontario--(Newsfile Corp. - March 25, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) (\"NuGen\"), a leader in needle-free drug delivery, today announced the filing of a new patent covering a Ready-to-Fill (RTF) COP/COC injection nozzle designed specifically for pharmaceutical needle-free applications. The nozzle, which is the subject of a newly filed patent application, represents a novel pharmaceutical packaging component that enables needle-free injection using established aseptic fill-finish processes, analogous to prefilled syringes but without a needle.The COP/COC nozzle architecture that is the subject of a newly filed patent application is optimized for high-pressure jet injection, combining dimensional stability, material consistency, and compatibility with pharmaceutical requirements. This enables scalable manufacturing of needle-free, prefilled drug delivery systems without reliance on traditional needles.The newly filed patent application underpins the Company's Prefilled Nozzle (PFN) platform, designed as an integrated drug-device system, combining a prefilled nozzle with a reusable auto-injector. Following aseptic filling, the nozzle functions as the primary drug container and is supplied ready for use, eliminating manual drug transfer steps at the point of care.Drug administration is enabled through a reusable auto-injector designed to accommodate multiple prefilled nozzle formats, including 0.5 mL and 1.0 mL long nozzles. Upon insertion, the injector automatically adapts to the nozzle configuration and delivers the full prefilled dose in a single activation. This auto-dosing capability allows pharmaceutical partners to support multiple dose presentations using one injector platform, while providing patients with a simple and consistent injection experience.\"According to Business Wire[1], the global prefilled syringe market is experiencing rapid growth, with most industry analyses projecting between 9% and 12% over the next several years, driven by self-administration and biologic therapies,\" said Nicky Canton, COO of NuGen. \"With this development, NuGen is extending its needle-free technology creating new opportunities for patient-centric differentiation.\" To support scalable pharmaceutical ...